Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Immune Checkpoint Inhibitors (ICI)-Related Dermatitis 1COVID-19 1

Interventions

Cyclophosphamide 27Busulfan 25fludarabine phosphate 24Antilymphocyte Serum 20Tacrolimus 18Peripheral Blood Stem Cell Transplantation 18Cyclosporine 15Radiotherapy 14Mycophenolic Acid 14Methotrexate 14Melphalan 12Filgrastim 11Whole-Body Irradiation 10Methylprednisolone 10Cord Blood Stem Cell Transplantation 9Etoposide 7Cytarabine 5sargramostim 4Thiotepa 4Thalidomide 4Specimen Handling 4Sirolimus 4Rituximab 4Cyclosporins 4Biopsy 4Alemtuzumab 4ruxolitinib 3Flow Cytometry 3Arsenic Trioxide 3thymoglobulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myelodysplastic-Myeloproliferative Diseases × Janus Kinase Inhibitors × Clear all
NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutchinson Cancer Center

Phase 2 Recruiting
50 enrolled
Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡